Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer

被引:0
作者
Chunyu Tian
Minghui Wang
Hancheng Liu
Jianping Liu
Mengze Xu
Lihui Ma
机构
[1] Affiliated Hospital of Chengde Medical University,Department of Breast Surgery
[2] Chengde Medical University,School of Nursing
来源
Irish Journal of Medical Science (1971 -) | 2023年 / 192卷 / 3期
关键词
HER2; breast cancer; Neoadjuvant therapy; Pathological response; Pyrotinib; TAC;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1041 / 1049
页数:8
相关论文
共 247 条
[1]  
Trayes KP(2021)Breast cancer treatment Am Fam Physician 104 171-178
[2]  
Cokenakes SEH(2020)Jemal A (2020) Cancer statistics CA Cancer J Clin 70 7-30
[3]  
Siegel RL(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
[4]  
Miller KD(2021)Current and future management of HER2-positive metastatic breast cancer JCO Oncol Pract 17 594-604
[5]  
Sung H(2022)Clinical trial data and emerging strategies: HER2-positive breast cancer Breast Cancer Res Treat 193 281-291
[6]  
Ferlay J(2021)The management of HER2-positive early breast cancer: current and future therapies Asia Pac J Clin Oncol 17 3-12
[7]  
Siegel RL(2013)Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer Breast Cancer Res Treat 142 549-558
[8]  
Laversanne M(2022)Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: a retrospective cohort study at FUSCC Breast 63 177-186
[9]  
Soerjomataram I(2021)Pertuzumab cardiotoxicity in patients with HER2-positive cancer: a systematic review and meta-analysis CJC Open 3 1372-1382
[10]  
Jemal A(2019)Trastuzumab-induced cardiomyopathy Cardiol Clin 37 407-418